KPV peptide research: what the colitis studies show and where the evidence stops
KPV peptide research rests on cell lines and mouse colitis models: nanomolar NF-κB inhibition via the PepT1 transporter, with no published human trials.
KPV peptide research centers on a three-amino-acid fragment, lysine-proline-valine, which is the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). Almost all of it comes from cultured cells and mouse colitis models. No controlled human trial appears in the published work reviewed here, and FDA has said it found no human exposure data for KPV.
This post covers the three studies most often cited for KPV, what each one measured, and where the evidence stops.
Research material: KPV at Fifth Ave Labs · KPV at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
What KPV is
KPV is written as alpha-MSH(11–13): residues 11 to 13 of the parent hormone. Alpha-MSH acts on melanocortin receptors. KPV is far smaller, and the papers below suggest it does not work mainly through those receptors.
Its size matters for how it enters cells. A tripeptide is a substrate for PepT1, a di- and tripeptide transporter. PepT1 is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease. For the side-chain properties of lysine, proline and valine, see the amino acid reference.
KPV peptide research on the PepT1 mechanism (2008)
Dalmasso and colleagues published the main mechanism paper in Gastroenterology in 2008. They used two human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and a human T-cell line (Jurkat). The cells were stimulated with pro-inflammatory cytokines, with or without KPV.
- NF-κB signaling. At 10 nM, KPV reduced IL-1β-induced NF-κB reporter activity in Caco2-BBE cells.
- Other pathways. Nanomolar KPV also inhibited MAP kinase signaling and reduced pro-inflammatory cytokine secretion.
- Transport. Human PepT1 carried KPV into Caco2-BBE cells, with a measured Km of about 160 µM.
The authors argued that the effect does not run through melanocortin receptors. They cited earlier work showing that KPV does not bind MC1, MC3 or MC5 receptors and does not compete with alpha-MSH.
The same paper tested KPV in two chemically induced mouse colitis models, DSS and TNBS. KPV was given orally. The authors reported less histological inflammation and lower pro-inflammatory cytokine mRNA in treated mice.
The MC1R-deficient mouse study (2008)
Kannengiesser and colleagues tested KPV in two colitis models, reported in Inflammatory Bowel Diseases. One was DSS colitis. The other was CD45RBhi T-cell transfer colitis, which is driven by immune cells rather than a chemical irritant.
- DSS colitis. Treated mice recovered earlier and regained more body weight. Inflammatory infiltrates and colonic myeloperoxidase (MPO) activity were both significantly lower.
- Transfer colitis. Treated mice recovered, regained weight and showed less histological inflammation.
- Nonfunctional MC1R. In mice lacking a working MC1 receptor, every animal in the KPV group survived DSS colitis.
The authors concluded that the effects "seem to be at least partially independent of MC1R signaling." The abstract does not report group sizes or effect sizes, so the strength of each result is hard to judge from it.
Nanoparticle delivery work (2017)
A 2017 study in Molecular Therapy by Xiao and colleagues loaded KPV into PLGA nanoparticles coated with hyaluronic acid. Hyaluronic acid binds CD44, which the authors describe as overexpressed on colonic epithelial cells and macrophages in colitis. The particles were carried in a chitosan/alginate hydrogel.
- Coated particles measured about 272 nm by light scattering, with a zeta potential near −5.3 mV.
- Encapsulation efficiency was 39.7% for coated particles, against 52.3% for uncoated ones.
- In DSS colitis (n = 5 per group), the coated-particle group had the smallest weight loss. Its TNF-α mRNA did not differ from healthy controls.
Some results were modest. The MPO difference between coated and uncoated particles was not statistically significant. Histology was described qualitatively, without scores.
How the three KPV studies compare
| Study | Model | Main reported finding | Key limit |
|---|---|---|---|
| Dalmasso et al., 2008 | Human cell lines; DSS and TNBS colitis in mice | NF-κB and MAP kinase inhibition at nanomolar KPV; uptake through PepT1 | Cell and rodent data only |
| Kannengiesser et al., 2008 | DSS and T-cell transfer colitis; MC1R-deficient mice | Weight regain, lower MPO, survival in MC1R-deficient mice | Abstract gives no group sizes |
| Xiao et al., 2017 | DSS colitis in mice | Hyaluronic-acid-coated nanoparticles outperformed uncoated ones on several measures | n = 5 per group; qualitative histology |
Where the evidence stops
All three studies are preclinical. They use cell lines and mice, mostly in chemically induced colitis, which is a model rather than the human disease. None reports human data.
FDA's review of KPV for compounding said it had not identified any human exposure data. Our explainer on the US legal categories for peptides covers that review. KPV is also one of six peptides in the October 2026 HHS interim compounding policy, which concerns pharmacy compounding, not laboratory research material.
For a framework on weighing this kind of evidence, see how to read preclinical research. Structure and lab-handling notes are on the KPV compound page.
Research material: KPV at Fifth Ave Labs · KPV at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Sources
- Gastroenterology: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso et al., 2008)
- Inflammatory Bowel Diseases: Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Kannengiesser et al., 2008)
- Molecular Therapy: Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (Xiao et al., 2017)
Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.
More from the blog
- Health Canada finds bacteria in seized peptide vials: the November 2026 advisories
- What is a peptide bond? Resonance, cis/trans isomers and how it forms and breaks
- Cagrilintide: what the amylin analog's trials show and where FDA review stands
- AMA urges HHS to rescind its peptide compounding policy as the comment period closes